A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

Salubris Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Postmenopausal Women With Osteoporosis

Treatments: Drug: Intervention Group 1; Drug: SAL056 56.5μg; Drug: Intervention Group 2; Drug: Intervention Group 3

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT07579936

SAL056A202

Details and patient eligibility

About

This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.

Full description

This study will randomly assign 200 eligible trial participants to either the intervention group or the control group, with each treatment group receiving an 8-week course of the investigational drug. By comparing the incidence of safety events between the groups at the end of the treatment period, the safety differences among the four different medication regimens will be evaluated.

The study is primarily divided into a screening period (up to 4 weeks before administration), a treatment period (8 weeks), and a safety follow-up period of 1 week, requiring a total of 7 visits.

Enrollment: 200 estimated patients

Sex: Female

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1.Female, with independent mobility, 45 years ≤ age ≤ 80 years; 2.Natural menopause for ≥3 years, or surgical menopause for ≥3 years (surgery must be performed after age 40); for women with surgical menopause, follicle-stimulating hormone >40 mIU/mL is required; 3.18 ≤ body mass index ≤ 30 kg/m²; 4.Previous definitive diagnosis of osteoporosis; 5.Patients who are able to independently go to the hospital to receive injections of the investigational drug; 6. Voluntarily participate in this trial and sign the informed consent form.

Exclusion criteria

1. Received teriparatide treatment within 1 month prior to screening;
2. Patients with secondary osteoporosis, such as Cushing's syndrome, hyperprolactinemia, malabsorption syndrome or various gastrointestinal diseases related to malabsorption (such as Crohn's disease, chronic pancreatitis, etc.), rheumatoid arthritis, gout, multiple myeloma, etc.;
3. Patients with other diseases affecting calcium or bone metabolism, including hyperparathyroidism or hypoparathyroidism, hyperthyroidism or hypothyroidism (patients with hyperthyroidism or hypothyroidism receiving stable treatment with normal hormone levels are eligible; or patients with hypothyroidism where 5.5 mIU/L < thyroid-stimulating hormone ≤ 10.0 mIU/L but free thyroxine is within normal range are eligible), osteogenesis imperfecta, osteomalacia, Paget's disease of bone, hypercalcemia, hypocalcemia, active urolithiasis, etc.;
4. Patients who require treatment with other anti-osteoporosis drugs during the trial or long-term/continuous use of digitalis glycosides such as digoxin;
5. Patients with severe renal disease (serum creatinine >1.5 times the upper limit of normal), uncontrolled hypertension [systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg], severe heart disease (such as myocardial infarction, unstable angina pectoris, heart failure with NYHA functional class III-IV, severe arrhythmias, etc.), cerebral infarction (excluding lacunar cerebral infarction) or occlusive arteriosclerosis, malignant tumors, and those with other serious underlying diseases;
6. Patients with esophageal abnormalities that cause delayed esophageal emptying (such as reflux esophagitis, esophageal stricture or achalasia) or those with difficulty swallowing;
7. Abnormal laboratory findings detected during the screening period, including any of the following abnormal indicators:

1) Alkaline phosphatase >1.3 times the upper limit of normal; 2) Alanine aminotransferase or aspartate aminotransferase >3.0 times the upper limit of normal; 3)Total bilirubin >1.5 times the upper limit of normal; 4) Glycated hemoglobin ≥8.5%; 5)White blood cell count <3.0×10⁹/L, or hemoglobin <100g/L, or platelet count <90×10⁹/L; 6)Parathyroid hormone >1.5 times the upper limit of normal; 8. Positive for hepatitis C virus antibody, or Treponema pallidum antibody, or human immunodeficiency virus antibody; or positive for hepatitis B surface antigen (HBsAg) with peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) titer ≥1×103 copies/mL (if HBsAg is positive and peripheral blood HBV DNA titer <1×103 copies/mL, the trial participant is eligible if the investigator considers the participant's chronic hepatitis B to be in a stable phase and will not increase the risk to the trial participant); 9. History of major surgery (excluding fracture surgery) within 6 months prior to signing the informed consent form, or planned major surgery during the study period; 10. Known history of organ transplantation; 11. History of drug abuse within 6 months prior to informed consent; 12. Individuals with known allergy to the investigational drug; 13. Patients who have previously received radiation therapy to the skeletal system; 14. Individuals with mental illness or cognitive impairment due to any cause; 15. Patients deemed unsuitable to participate in this study by researchers based on risk-benefit considerations.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 4 patient groups

Control group

Experimental group

Description:

SAL056 56.5μg administered once weekly for 8 weeks

Treatment:

Drug: SAL056 56.5μg

Intervention Group 1

Other group

Description:

Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks;

Treatment:

Drug: Intervention Group 1

Intervention Group 2

Other group

Description:

Teriparatide Injection daily formulation administered for 4 weeks, followed by SAL056 for 4 weeks;

Treatment:

Drug: Intervention Group 2

Intervention Group 3

Other group

Description:

SAL056 28.2μg administered twice weekly for 8 weeks.

Treatment:

Drug: Intervention Group 3